



Marksans Pharma Ltd.

5<sup>th</sup> February, 2019

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza  
C-1, Block 'G' Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051.  
Scrip Code: **MARKSANS**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort,  
Mumbai – 400 001.  
Scrip Code: **524404**

**PRESS RELEASE**

**Marksans Pharma Limited announces UK MHRA grant of Marketing Authorisation for Loratadine 5mg/5ml Oral Solution**

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that UK MHRA has granted Marketing Authorisation to its wholly owned subsidiary, Relonchem Limited, UK for Loratadine 5mg/5ml Oral Solution for the UK markets. The product will be manufactured in its UK facility. Loratadine Oral Solution is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children.

Thanking you.

Yours faithfully,  
For **Marksans Pharma Limited**

**Harshad Patel**  
**Asst. Company Secretary**

**Marksans Pharma Ltd.**

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com  
www.marksanspharma.com